Literature DB >> 21926612

Alveolar fibrocyte percentage is an independent predictor of poor outcome in patients with acute lung injury.

Christophe Quesnel1, Pascale Piednoir, Julien Gelly, Laurent Nardelli, Marc Garnier, Véronique Leçon, Sigismond Lasocki, Lila Bouadma, Ivan Philip, Carole Elbim, France Mentré, Paul Soler, Bruno Crestani, Monique Dehoux.   

Abstract

OBJECTIVE: Fibrocytes are mesenchymal progenitors involved in normal and pathologic repair. The aims of this study were: 1) to quantify fibrocytes in bronchoalveolar lavage fluid from patients with or without acute lung injury and acute respiratory distress syndrome; and 2) to evaluate the prognostic value of bronchoalveolar lavage fibrocyte percentage in patients with acute lung injury and acute respiratory distress syndrome.
DESIGN: Prospective cohort study.
SETTING: Three intensive care units of a large tertiary referral center. PATIENTS: One hundred twenty-two ventilated patients requiring bronchoalveolar lavage were enrolled (62 acute respiratory distress syndrome, 30 acute lung injury, 30-ventilated patients without acute lung injury and acute respiratory distress syndrome).
INTERVENTIONS: After bronchoalveolar lavage collection during standard care, the patients were followed up for 28 days and clinical outcome was recorded. Fibrocytes (CD45+/collagen 1+) were quantified in bronchoalveolar lavage by flow cytometry. Comparison of bronchoalveolar lavage fibrocyte percentage from patients with or without acute lung injury and acute respiratory distress syndrome was performed using a Wilcoxon test. A multivariate analysis using a Cox model was performed to study the independent predictors of survival.
MEASUREMENTS AND MAIN RESULTS: Fibrocytes were detected in 90 of 92 (98%) bronchoalveolar lavages from patients with acute lung injury and acute respiratory distress syndrome. The median percentage of bronchoalveolar lavage fibrocytes was significantly higher in patients with acute lung injury and acute respiratory distress syndrome (5.0%) in comparison with ventilated control subjects (0.9%, p < .0001). After adjustment for age, comorbidity of malignancy, and severity of illness, a bronchoalveolar lavage fibrocyte percentage >6% was independently associated with a higher 28-day mortality in patients with acute lung injury and acute respiratory distress syndrome (hazard ratio [95% confidence interval] 6.15 [2.78-13.64], p ≤ .0001). Addition of bronchoalveolar lavage fibrocyte percentage in a clinical model predicting mortality in patients with acute lung injury and acute respiratory distress syndrome improved global fit and discriminatory capacity (c-statistic, 0.78-0.85; p = .007).
CONCLUSIONS: Fibrocytes are detectable in bronchoalveolar lavage during acute lung injury and acute respiratory distress syndrome. A bronchoalveolar lavage fibrocyte percentage >6% provides an additive prognostic value to clinical predictors and may be useful to identify patients with acute lung injury and acute respiratory distress syndrome at highest risk of an adverse outcome.

Entities:  

Mesh:

Year:  2012        PMID: 21926612     DOI: 10.1097/CCM.0b013e31822d718b

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

Review 1.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

Review 2.  Concise review: current status of stem cells and regenerative medicine in lung biology and diseases.

Authors:  Daniel J Weiss
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

Review 3.  Fibrocytes: emerging effector cells in chronic inflammation.

Authors:  Hong Peng; Erica L Herzog
Journal:  Curr Opin Pharmacol       Date:  2012-03-30       Impact factor: 5.547

Review 4.  The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance.

Authors:  Ellen L Burnham; William J Janssen; David W H Riches; Marc Moss; Gregory P Downey
Journal:  Eur Respir J       Date:  2013-03-21       Impact factor: 16.671

5.  Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment.

Authors:  Brian T Garibaldi; Franco R D'Alessio; Jason R Mock; D Clark Files; Eric Chau; Yoshiki Eto; M Bradley Drummond; Neil R Aggarwal; Venkataramana Sidhaye; Landon S King
Journal:  Am J Respir Cell Mol Biol       Date:  2012-09-20       Impact factor: 6.914

Review 6.  Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome.

Authors:  Nuria E Cabrera-Benitez; John G Laffey; Matteo Parotto; Peter M Spieth; Jesús Villar; Haibo Zhang; Arthur S Slutsky
Journal:  Anesthesiology       Date:  2014-07       Impact factor: 7.892

7.  Clinical review: Respiratory monitoring in the ICU - a consensus of 16.

Authors:  Laurent Brochard; Greg S Martin; Lluis Blanch; Paolo Pelosi; F Javier Belda; Amal Jubran; Luciano Gattinoni; Jordi Mancebo; V Marco Ranieri; Jean-Christophe M Richard; Diederik Gommers; Antoine Vieillard-Baron; Antonio Pesenti; Samir Jaber; Ola Stenqvist; Jean-Louis Vincent
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

8.  Relation between Red Cell Distribution Width and Mortality in Critically Ill Patients with Acute Respiratory Distress Syndrome.

Authors:  Benji Wang; Yuqiang Gong; Binyu Ying; Bihuan Cheng
Journal:  Biomed Res Int       Date:  2019-03-21       Impact factor: 3.411

9.  Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis.

Authors:  Yishan Wang; Huijuan Wang; Chunfang Zhang; Chao Zhang; Huqin Yang; Ruiyue Gao; Zhaohui Tong
Journal:  Crit Care       Date:  2019-02-12       Impact factor: 9.097

10.  Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis.

Authors:  Raphael Borie; Christophe Quesnel; Sophie Phin; Marie-Pierre Debray; Joelle Marchal-Somme; Kiet Tiev; Marcel Bonay; Aurélie Fabre; Paul Soler; Monique Dehoux; Bruno Crestani
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.